Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment

Journal of Alzheimer's Disease

Volumn 40, Issue 4, 2014, Pages 919-927

  Balasa, Mircea ^a   Sánchez Valle, Raquel ^a,b   Antonell, Anna ^a   Bosch, Beatriz ^a   Olives, Jaume ^a   Rami, Lorena ^a   Castellví, Magda ^a   Molinuevo, José Luis ^a,b   Lladó, Albert ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

CSF biomarkers; early onset Alzheimer's disease; NIA AA criteria

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX ATROPHY; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; EARLY ONSET COGNITIVE IMPAIRMENT; FEMALE; FOLLOW UP; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL NEUROIMAGING; GENETIC SCREENING; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; PRIMARY PROGRESSIVE APHASIA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; CEREBROSPINAL FLUID; CLASSIFICATION; COGNITION DISORDERS; GENETICS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY;

ADULT; AGED; APOLIPOPROTEINS E; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; GENETIC TESTING; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84901763185     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132195     Document Type: Article

References (37)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
2. Stopford CL, Snowden JS, Thompson JC, Neary D (2008) Variability in cognitive presentation of Alzheimer's disease. Cortex 44, 185-195.
3. Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA (2010) Early-versus late-onset Alzheimer's disease: More than age alone. J Alzheimers Dis 19, 1401-1408.
4. Mendez MF, Lee AS, Joshi A, Shapira JS (2012) Nonamnestic presentations of early-onset Alzheimer's disease. Am J Alzheimers Dis Other Demen 27, 413-420.
5. Shinagawa S, Ikeda M, Toyota Y, Matsumoto T, Matsumoto N, Mori T, Ishikawa T, Fukuhara R, Komori K, Hokoishi K, Tanabe H (2007) Frequency and clinical characteristics of early-onset dementia in consecutive patients in a memory clinic. Dement Geriatr Cogn Disord 24, 42-47.
6. Galton CJ, Patterson K, Xuereb JH, Hodges JR (2000) Atypical and typical presentations of Alzheimer's disease: A clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 123(Pt 3), 484-498.
7. Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, Hodges JR (2007) Focal cortical presentations of Alzheimer's disease. Brain 130, 2636-2645.
8. Ling H, O'Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR, Paviour DC, Lees AJ (2010) Does corticobasal degeneration exist? A clinicopathological reevaluation. Brain 133, 2045-2057.
9. Balasa M, Gelpi E, Antonell A, Rey MJ, Sanchez-Valle R, Molinuevo JL, Llado A (2011) Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology 76, 1720-1725.
10. Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, Boeve BF, Parisi JE, Petersen RC, Dickson DW, Jack CR, Jr. (2008) Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 63, 204-212.
11. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009) Cerebrospinal fluid betaamyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66, 382-389.
12. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
13. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA302, 385-393.
14. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of betaamyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98-106.
15. Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, Van Swieten JC, Scheltens P (2004) Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62, 1580-1584.
16. Beach TG, Monsell SE, Phillips LE, KukullW(2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 71, 266-273.
17. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
18. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
19. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, PijnenburgY, ChowTW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456-2477.
20. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M (2011) Classification of primary progressive aphasia and its variants. Neurology 76, 1006-1014.
21. PetersenRC(2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194.
22. Grober E, Buschke H, Crystal H, Bang S, Dresner R (1988) Screening for dementia by memory testing. Neurology 38, 900-903.
23. Mesulam MM (1982) Slowly progressive aphasia without generalized dementia. Ann Neurol 11, 592-598.
24. Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE, Crook R, Caselli RJ, Knopman DS, Petersen RC (2004) Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 63, 1168-1174.
25. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 51, 1546-1554.
26. Antonell A, Fortea J, Rami L, Bosch B, Balasa M, Sanchez- Valle R, Iranzo A, Molinuevo JL, Llado A (2011) Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. J Neural Transm 118, 259-262.
27. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, Skoog I, Wallin A, Wahlund LO, Marcusson J, Nagga K, Andreasen N, Davidsson P, Vanmechelen E, Blennow K (2001) Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values. Clin Chem 47, 1776-1781.
28. Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki HW, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J, Bibl M (2009) Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm 116, 203-212.
29. Antonell A, Gil S, Sanchez-Valle R, Balasa M, Bosch B, Prat MC, Chiollaz AC, Fernandez M, Yague J, Molinuevo JL, Llado A (2012) Serum progranulin levels in patients with frontotemporal lobar degeneration and Alzheimer's disease: Detection ofGRNmutations in a Spanish cohort. J Alzheimers Dis 31, 581-591.
30. Bouwman FH, Schoonenboom NS, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, Scheltens P, van der Flier WM (2009) CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging 30, 1895-1901.
31. Mattsson N, Rosen E, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek MM, Olde Rikkert M, Tsolaki M, Mulugeta E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Wallin A, Eriksdotter-Jonhagen M, Minthon L, Winblad B, Blennow K, Zetterberg H (2012) Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 78, 468-476.
32. Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69, 2197-2204.
33. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C (2009) Age, neuropathology, and dementia. N Engl J Med 360, 2302-2309.
34. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78, 47-54.
35. Perry DC, Lehmann M, Yokoyama JS, Karydas A, Lee JJ, Coppola G, Grinberg LT, Geschwind D, Seeley WW, Miller BL, Rosen H, Rabinovici G (2013) Progranulin mutations as risk factors for Alzheimer disease. JAMA Neurol 70, 774-778.
36. Wojtas A, Heggeli KA, Finch N, Baker M, Dejesus- Hernandez M, Younkin SG, Dickson DW, Graff-Radford NR, Rademakers R (2012) C9orf72 repeat expansions and other FTD gene mutations in a clinicalADpatient series from Mayo Clinic. Am J Neurodegener Dis 1, 107-118.
37. Lowe VJ, Peller PJ, Weigand SD, Montoya Quintero C, Tosakulwong N, Vemuri P, Senjem ML, Jordan L, Jack CR, Jr., Knopman D, Petersen RC (2013) Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. Neurology 80, 2130-2137.